Maintaining genomic integrity by protecting against various types of DNA damage is an essential process for all living creatures. Studies of mammalian mechanisms involved in responding to and repairing damaged DNA revealed that there are comprehensive coordinated pathways activated that regulate the DNA damage response (DDR) and DNA repair[@b1],[@b2]. Investigations have demonstrated that cells with atypical expression of prominent proteins involved in these pathways frequently displayed altered sensitivity to DNA damaging agents such as ionizing radiation or many chemotherapeutic drugs[@b3]. These findings led to a rapid interest in exploring targeting DDR proteins (mainly through inhibition) to increase the effectiveness of cancer therapeutics (termed radiosensitization and chemosensitization). While several approaches have been developed successfully in this direction, achieving tumor selectivity remains a critical challenge to the molecular targeted cancer therapy.

DDR and DNA Repair {#s2}
==================

The optimal DDR deals with environmental or endogenous insults to DNA to prevent genetic instability and promote survival ([Figure 1](#cjc-31-08-359-g001){ref-type="fig"}). Activation of cell cycle checkpoints, which slows down cell cycle progression, is one of the early steps in the DDR. The overall function of cell cycle checkpoints is to provide time for damage detection and appropriate DNA repair[@b4]. With optimal DNA repair, cells are sometimes able to recover from the damage and resume normal cell growth. On the other hand, when the damage is irreparable, programmed cell death is triggered. To deal with various types of DNA damage, the mammalian DNA repair system includes mechanisms such as base excision repair (BER), nucleotide excision repair (NER), mismatch repair (MMR), non-homologous end joining (NHEJ), and homologous recombination (HR)[@b5]. Altogether, the DDR and DNA repair systems are orchestrated by a comprehensive signaling network controlling processes from transcriptional regulation to posttranslational modifications. Several categories of proteins have been extensively studied, including damage sensors, transducers, mediators and effectors[@b6]. Sensors are typically chromatin-bound proteins that recognize DNA damage and recruit transducers. Transducers can amplify damage response signals by posttranslational modifications, such as phosphorylation. Mediators are critical for transducers to recognize downstream effectors and may be critical for the signal on/off switch. Effectors negatively regulate cell cycle progression and might also be critical for activation of DNA repair or apoptosis. Overall, many of these evolutionarily conserved gene products that are critical for DDR and DNA repair have been explored as potential targets for cancer therapy[@b7].
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Targeting the DDR for Radiosensitization and Chemosensitization {#s3}
===============================================================

Several major kinases that play a critical role in the DDR have been extensively investigated for developing small molecules to enhance sensitivity to radiotherapy and chemotherapy. These druggable kinases include the ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Well conserved through evolution, ATM and DNA-PKcs are family members of the phosphatidylinositol-3 (PI-3) kinase-related kinase family, and mutation of the ATM kinase causes ataxia telangiectasia manifested by neurodegeneration, cancer, immunodeficiency, and hyper-radiosensitivity[@b8]. Early studies show that PI-3 kinase inhibitors such as wortmannin and LY294002 can inhibit ATM, the ATM and Rad3-related kinase (ATR), and DNA-PKcs to achieve radiosensitization[@b9],[@b10]. More specific inhibitors of ATM (KU55933, KU60019, and CP466722) have been developed and showed impressive *in vitro* activity as radiosensitizers and chemosensitizers[@b11]--[@b13]. For DNA-PKcs, small molecules such as Nu7441, IC8736 (flavone-based inhibitor), and SU11752 (ATP competitive inhibitor) have shown promising sensitization effects, despite significant cytotoxicity due to inhibition of the NHEJ process[@b14]--[@b16]. The bottleneck of developing radiosensitizers and chemosensitizers is to achieve specificity and selectivity. Since ATM (as well as DNA-PKcs) is a master controller of DDR, determining the specific downstream pathway regulating radiosensitivity is critical for development of inhibitors. In addition to small molecules, small peptides targeting Chk2 kinase activation[@b17], the ATM-NBS1 interaction[@b18], and DNA-PKcs autophosphorylation[@b19] have been reported to possess radiosensitization activity *in vitro*. These studies used fusion peptides containing a domain for internalization and an interference domain for specific pathway targeting. Although small inhibitory peptides provide specificity for signaling pathways targeted, concerns regarding the stability as well as the potential for the immunogenicity of fusion peptides limit further clinical development.

Targeting DDR for Synthetic Lethality {#s4}
=====================================

A critical challenge for molecular targeted cancer therapy is how to discriminate tumor and normal cells. Traditional chemotherapeutic drugs are cytotoxic because they affect DNA synthesis. Since tumor cells typically have a high proliferation rate, cytotoxic drugs prevail against tumor cells. On the other hand, overexpression of some oncoproteins has been explored for molecular targeted therapy. Synthetic lethality, which is caused by a combination of two genetic mutations that lead to cell death, is one emerging strategy for molecular targeted cancer therapy[@b20]. Since suboptimal DDR and DNA repair are well recognized in cancer cells, it is likely that when one DDR protein has been functionally mutated, an additional functional mutation on a different protein can result in cell death. This concept offers an intriguing strategy for developing anti-cancer therapies.

One example of successfully targeting DNA repair for synthetic lethality is the use of poly (ADPribose)poly-merase (PARP) inhibitors in *BRCA1/BRCA2*-mutant breast cancer or ovarian cancer cells[@b21],[@b22]. BRCA1/BRCA2 are critical elements in HR-based repair of DNA double strand breaks[@b17]. *BRCA1* and *SRCA2* are frequently mutated in breast cancer and ovarian cancer patients, and mutation of these genes leads to inefficient DNA DSB repair. On the other hand, PARP binds to single-strand breaks (SSBs) and facilitates SSB repair. Inhibition of PARP results in persistent SSBs, resulting in replication-associated DSBs that could be lethal for HR-defective tumors. This makes PARP inhibitors a thousand times more toxic in *BRCA*-mutant cells. Promising preclinical studies have led to the development of several inhibitors including iniparid, olaparib, PF-01367338, veliparib, and CEP-9722 for clinical trials[@b7].

Using small interfering RNA (siRNA) screening, investigators are also currently working to identify additional HR repair genes that can mediate synthetic lethality with PARP1 inhibition[@b23]. Genes involved in NER (such as *DDB1* and *XAB2*) and the tumor suppressor gene *PTEN* have been found to be synthetically lethal with a PARP inhibitor[@b23],[@b24]. BRIT1, a chromatin-binding protein required for recruitment of many important DDR proteins such as ATM, MDC1, NBS1, RAD51, and BRCA2 to DNA damage sites, also shows synthetic lethality with PARP inhibitors[@b25],[@b26]. In addition, tankyrase 1, another PARP family member involved largely in telomere maintenance, shows synthetic lethality with BRCA1 deficiency[@b27]. A recent study demonstrated that mantle cell lymphoma (MCL) cells deficient in both ATM and p53 are more sensitive to PARP inhibition than cells lacking ATM function alone or their normal counterparts[@b28].

Despite promising early clinical results[@b29], iniparib combined with chemotherapy failed to demonstrate any survival improvement in triple-negative metastatic breast cancer patients in a randomized phase III clinical trial (American Society of Clinical Oncology 2011 Annual meeting report). This study raises concerns about the clinical significance of PARP inhibition and has since attracted extensive discussion[@b30]. One major concern is that there are additional, yet unidentified molecular factors that may affect PARP1 inhibitors[@b28]. Synthetic lethality might be compromised because cancers may employ multiple pathways to overcome a defect in one DNA repair pathway[@b31]. More importantly, the tumor specificity of many DNA repair components is not well defined. Since iniparib is less potent than most of other compounds under development, there are concerns whether iniparib should represent a PARP inhibitor in clinical studies. Recent studies have shown that iniparib, which can modify cysteine-containing proteins nonselec-tively in tumor cells, is not a *bona fide* inhibitor of PARP, and cautions against comparing clinical trial results using iniparib with other PARP inhibitors[@b32]. Further, another article published afterwards supports the finding that iniparib does not actually inhibit PARP *in vitro* and concludes that iniparib is not suitable for clinical studies involving PARP inhibition[@b33]. Unrelated to the molecular mechanisms, a concern has been raised that patient "cross-over" in the randomized clinical trial might partially contribute to the negative clinical result[@b34]. Together, these studies indicate that despite the disappointing phase III clinical trials of iniparib, studies should continue to investigate clinical benefits of PARP inhibitors. Further clinical trials using verified, specific inhibitors of PARP as monotherapy and/or in combination with radiotherapy and chemotherapy are greatly anticipated. Studies on the mechanisms of synthetic lethality would help identify critical patient populations that will benefit from the therapy. Meanwhile, further research on identifying inhibitors of other potential DDR targets in a variety of tumor tissue types will broaden the applicability of this strategy.
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